Effects of an Anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: Optimizing methods to quantify vascular changes

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 3, 2008, Pages 1178-1183

  Campa, Claudio ^a,b   Kasman, Ian ^a   Ye, Weilan ^a   Lee, Wyne P ^a   Fuh, Germaine ^a   Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INTERCELLULAR ADHESION MOLECULE 2 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G6 31; PLANT LECTIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; DEXTRAN; DIAGNOSTIC AGENT; FLUORESCEIN DERIVATIVE; FLUORESCEIN DEXTRAN; FLUORESCEIN-DEXTRAN; TOMATO LECTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIODE LASER; EVALUATION; EXPERIMENTAL MODEL; FEMALE; FLUORESCENCE; FLUORESCENCE ANGIOGRAPHY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SUBRETINAL NEOVASCULARIZATION; TECHNIQUE; VALIDITY; ANIMAL; C57BL MOUSE; CHOROID; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LOW LEVEL LASER THERAPY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CHOROID; CHOROIDAL NEOVASCULARIZATION; DEXTRANS; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; FLUORESCEINS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; LASER THERAPY; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; PLANT LECTINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 41949083415     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1194     Document Type: Article

References (29)

1. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137:496-503.
2. Ryan SJ. The development of an experimental model of subretinal neovascularization in disciform macular degeneration. Trans Am Ophthalmol Soc. 1979;77:707-745.
3. Yi X, Ogata N, Komada M, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol. 1997;235:313-319.
4. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
5. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med. 2007;58:491-504.
6. Edelman JL, Castro MR. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp Eye Res. 2000;71: 523-533.
7. Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol. 2004;340: 1073-1093.
8. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem. 2006;281:951-961.
9. D'Amato R, Wesolowski E, Smith LE. Microscopic visualization of the retina by angiography with high-molecular-weight fluoresceinlabeled dextrans in the mouse. Microvasc Res. 1993;46:135-142.
10. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised agerelated macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
11. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37: 1929-1934.
12. Wells JA, Murtry R, Chibber H, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularization. Br J Ophthalmol. 1996;80:363-366.
13. Ishibashi T, Mata Y, Yohikawa M, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1997;235:159-167.
14. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:241-248.
15. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
16. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, and the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
17. Rosenfeld PJ, Brown DM, Heier JS, et al., and the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
18. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355: 1409-1412.
19. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008; 49:522-527.
20. Semkova I, Peters S, Welsandt G, Janicki H, Jordan J, Schraermeyer U. Investigation of laser-induced choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci. 2003;44:5349-5354.
21. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3578-3585.
22. Shi X, Semkova I, Muther PS, Dell S, Kociok N, Joussen AM. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res. 2006;83:1325-1334.
23. Odergren A, Ming Y, Kvanta A. Photodynamic therapy of experimental choroidal neovascularization in the mouse. Curr Eye Res. 2006;31:765-774.
24. Danguy A, Decaestecker C, Genten F, Salmon I, Kiss R. Applications of lectins and neoglycoconjugates in histology and pathology. Acta Anat (Basel). 1998;161:206-218.
25. Sakurai E, Taguchi H, Anand A, et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:2743-2749.
26. Debbage PL, Griebel J, Ried M, Gneiting T, DeVries A, Hutzler P. Lectin intravital perfusion studies in tumor-bearing mice: micrometer-resolution, wide-area mapping of microvascular labeling, distinguishing efficiently and inefficiently perfused microregions in the tumor. J Histochem Cytochem. 1998;46:627-639.
27. Bora PS, Hu Z, Tezel TH, et al. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proc Natl Acad Sci U S A. 2003;100:2679-2684.
28. Lambert V, Munaut C, Noel A, et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 2001;15:1021-1027.
29. Campos M, Amaral J, Becerra SP, Fariss RN. A novel imaging technique for experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2006;47:5163-5170.